Practice Point® CME Podcasts: Expert Discussions in Oncology™

About Practice Point® CME Podcasts: Expert Discussions in Oncology™

Join leading experts in the field of oncology as they explore the latest advancements, trends, and challenges in cancer care. From cutting-edge treatments and clinical trials to the human stories behind the science, each episode delves deep into the evolving landscape of oncology. If you’re seeking AMA, ABS, ANCC, or ACPE credit, these podcasts offer valuable knowledge, expert perspectives, and real-world insights to help you better understand cancer and its impact on individuals and society.

Publisher

Practice Point Communications

Category

education

Language

en

Explicit

No

First episode

19 Jan 2025

Latest episode

19 Jan 2025

Latest episodes

14 episodes in the feed.

1. 

   19 Jan 2025

   Episode 14 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 3

   Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes. Launch Date: December 5, 2024 Release Date: December 5, 2024 Expiration Date: November 30, 2025 FACULTY Aditya Bardia, MD, MPH, FASCO Associate Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital Dana-Farber/Harvard Cancer Center, Boston, MA Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology Program The University of Chicago Medicine Chicago, IL his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19 (https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19)

2. 

   19 Jan 2025

   Episode 13- Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 2

   Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes. Launch Date: December 5, 2024 Release Date: December 5, 2024 Expiration Date: November 30, 2025 FACULTY Aditya Bardia, MD, MPH, FASCO Associate Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital Dana-Farber/Harvard Cancer Center, Boston, MA Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology Program The University of Chicago Medicine Chicago, IL his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19 (https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19)

3. 

   19 Jan 2025

   Episode 12 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 1

   Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes. Launch Date: December 5, 2024 Release Date: December 5, 2024 Expiration Date: November 30, 2025 FACULTY Aditya Bardia, MD, MPH, FASCO Associate Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital Dana-Farber/Harvard Cancer Center, Boston, MA Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology Program The University of Chicago Medicine Chicago, IL his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19 (https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19)

4. 

   19 Jan 2025

   Episode 11 - NF1-PN: Improving Diagnosis and Monitoring While Integrating Ongoing Updates in the Treatment Continuum

   Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients. Launch Date: October 31, 2024 Release Date: October 31, 2024 Expiration Date: September 30, 2025 FACULTY Amy Armstrong, MD Assistant Professor of Pediatrics Division of Hematology/Oncology Neurofibromatosis (NF) Center Washington University School of Medicine St. Louis, Missouri This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/neurofibromatosis-type-1-related-plexiform-neurofibromas-improving-diagnosis-and-monitoring-while-integrating-ongoing-updates-in-the-treatment-continuum-1 (https://www.practicepointcme.com/CMEHome/neurofibromatosis-type-1-related-plexiform-neurofibromas-improving-diagnosis-and-monitoring-while-integrating-ongoing-updates-in-the-treatment-continuum-1)

5. 

   19 Jan 2025

   Episode 10 - Podcasts in NSCLC Harboring EGFR Mutations: Cutting-Edge Reports from ASCO 2024

   This is an accredited continuing education podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice. Launch Date: June 5, 2024 Release Date: June 5, 2024 Expiration Date: May 31, 2025 FACULTY BIO Stephen Liu, MD Associate Professor of Medicine Director of Thoracic Oncology Director of Developmental Therapeutics Lombardi Comprehensive Cancer Center Georgetown University This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/podcasts-in-nsclc-harboring-egfr-mutations-cutting-edge-reports-from-asco-2024 (https://www.practicepointcme.com/CMEHome/podcasts-in-nsclc-harboring-egfr-mutations-cutting-edge-reports-from-asco-2024)

6. 

   19 Jan 2025

   Episode 9 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer - Part 3: Implementing HRRm Testing in Practice

   This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients. Launch Date: May 30, 2024 Release Date: May 30, 2024 Expiration Date: April 30, 2025 FACULTY BIO Andrew Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Duke University Tanya Dorff, MD Professor of Medicine City of Hope This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8 (https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8)

7. 

   19 Jan 2025

   Episode 8 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer - Part 2: Guidelines for HRRm Testing

   This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients. Launch Date: May 30, 2024 Release Date: May 30, 2024 Expiration Date: April 30, 2025 FACULTY BIO Andrew Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Duke University Tanya Dorff, MD Professor of Medicine City of Hope This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8 (https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8)

8. 

   19 Jan 2025

   Episode 7 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer - Part 1: Rationale for HRRm Testing in Metastatic Prostate Cancer

   This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients. Launch Date: May 30, 2024 Release Date: May 30, 2024 Expiration Date: April 30, 2025 FACULTY BIO Andrew Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Duke University Tanya Dorff, MD Professor of Medicine City of Hope This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8 (https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8)

9. 

   19 Jan 2025

   Episode 6 - Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Part 3: Optimizing use of ADCs

   This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients. Launch Date: December 29, 2023 Release Date: December 29, 2023 Expiration Date: November 30, 2024 FACULTY BIOS Benjamin Levy, MD Associate Professor of Oncology Johns Hopkins Medicine Aaron Lisberg, MD Assistant Professor of Clinical Medicine University of California, Los Angeles Alexander Spira, MD, PhD, FACP Co-Director Virginia Cancer Specialists Research Institute This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode .https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1 (https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1)

10. 

    19 Jan 2025

    Episode 5 - Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Part 2: Impact of ADCs

    This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients. Launch Date: December 29, 2023 Release Date: December 29, 2023 Expiration Date: November 30, 2024 FACULTY BIOS Benjamin Levy, MD Associate Professor of Oncology Johns Hopkins Medicine Aaron Lisberg, MD Assistant Professor of Clinical Medicine University of California, Los Angeles Alexander Spira, MD, PhD, FACP Co-Director Virginia Cancer Specialists Research Institute This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode .https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1 (https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1)

11. 

    19 Jan 2025

    Episode 4 - Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Part 1: Rationale for ADCs

    This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients. Launch Date: December 29, 2023 Release Date: December 29, 2023 Expiration Date: November 30, 2024 FACULTY BIOS Benjamin Levy, MD Associate Professor of Oncology Johns Hopkins Medicine Aaron Lisberg, MD Assistant Professor of Clinical Medicine University of California, Los Angeles Alexander Spira, MD, PhD, FACP Co-Director Virginia Cancer Specialists Research Institute This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode .https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1 (https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1)

12. 

    19 Jan 2025

    Episode 3 - Treatment Progress in Triple Negative Breast Cancer – Improving Disparities and Outcomes with New Approaches - Part 3: Addressing Disparities

    In this podcast, Drs. William Gradishar, Yuan Yuan and Rita Nanda will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care. Launch Date: November 9, 2023 Release Date: November 9, 2023 Expiration Date: October 31, 2024 FACULTY BIOS Dr. William Gradishar is the Chief of Hematology and Oncology in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Yuan Yuan is the Director of Breast Cancer Research at Cedar-Sinai Medical Center in Los Angeles, California. Dr. Rita Nanda is the Associate Professor of Medicine at the University of Chicago Medicine in Chicago, Illinois. This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32 (https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32)

13. 

    19 Jan 2025

    Episode 2 - Treatment Progress in Triple Negative Breast Cancer – Improving Disparities and Outcomes with New Approaches - Part 2: Individualized Metastatic BC Treatment

    In this podcast, Drs. William Gradishar, Yuan Yuan and Rita Nanda will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care. Launch Date: November 9, 2023 Release Date: November 9, 2023 Expiration Date: October 31, 2024 FACULTY BIOS Dr. William Gradishar is the Chief of Hematology and Oncology in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Yuan Yuan is the Director of Breast Cancer Research at Cedar-Sinai Medical Center in Los Angeles, California. Dr. Rita Nanda is the Associate Professor of Medicine at the University of Chicago Medicine in Chicago, Illinois. This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32 (https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32)

14. 

    19 Jan 2025

    Episode 1 - Treatment Progress in Triple Negative Breast Cancer – Improving Disparities and Outcomes with New Approaches - Part 1: Biology and Burden

    In this podcast, Drs. William Gradishar, Yuan Yuan and Rita Nanda will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care. Launch Date: November 9, 2023 Release Date: November 9, 2023 Expiration Date: October 31, 2024 FACULTY BIOS Dr. William Gradishar is the Chief of Hematology and Oncology in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Yuan Yuan is the Director of Breast Cancer Research at Cedar-Sinai Medical Center in Los Angeles, California. Dr. Rita Nanda is the Associate Professor of Medicine at the University of Chicago Medicine in Chicago, Illinois. This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32 (https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32)

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Podcast Authority Score: 9 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

18

Social presence

0

YouTube

0

Engagement

0

Contact Practice Point® CME Podcasts: Expert Discussions in Oncology™

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.